Richard Colonno, chief scientific officer of Presidio, said: “Numerate has a very promising computational approach that we believe will help expand our HCV portfolio in a highly competitive area encumbered by many patents.”
Richard Colonno, chief scientific officer of Presidio, said: “Numerate has a very promising computational approach that we believe will help expand our HCV portfolio in a highly competitive area encumbered by many patents.”